Latest News

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Compared with placebo, adult patients with ADHD and comorbid anxiety had greater change from baseline in AISRS total score at week 8.

In an interview with Pharmacy Times, Alison Newman, MPH, program operations specialist with the Center for Community-Engaged Drug Education, Epidemiology & Research at the Addictions, Drug & Alcohol Institute at the University of Washington, discusses the significance of OTC naloxone availability and the barriers that remain despite the introduction of additional products.

The European Commission approved tolebrutinib as the first therapy targeting disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (SPMS).

Oral semaglutide delivers significant weight loss in OASIS trials, offering needle-free obesity therapy.

Evaluating, implementing, and optimizing automation technologies that improve safety, efficiency, and patient care outcomes are practical strategies for health-system pharmacy leaders.

This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.

Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.

Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when the program launches.

The agent is to be used alongside diet adjustments in adult patients.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

Marijuana’s move to Schedule III has reignited a long-standing contradiction.

Pharmacists should be up-to-date on current outbreak status, US risk level, and how to recognize warning signs and counsel concerned patients as confirmed Ebola cases caused by Bundibugyo ebolavirus continue to rise across the Democratic Republic of the Congo (DRC) and Uganda.

The new indication is for those aged 12 years and older with unresectable or metastatic SS who received prior chemotherapy and are positive for certain genetic subtypes.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Understanding this rapidly evolving therapeutic landscape will be essential as obesity pharmacotherapy continues to transform diabetes and cardiometabolic care.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Specialty dispensing and infusion services offer real opportunity—but the path requires careful planning, sequencing, and the right resources.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.